Why CalciMedica, Inc.’s (CALC) Stock Is Down 82.41%
As of Wednesday, January 28, CalciMedica, Inc.’s CALC share price has dipped by 82.41%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.
Commentary & Analysis
Why CalciMedica, Inc.’s (CALC) Stock Is Down 77.54%
As of Wednesday, January 28, CalciMedica, Inc.’s CALC share price has dipped by 77.54%, which has investors questioning if this is right time to buy.Tudor Pop
Why CalciMedica, Inc.’s (CALC) Stock Is Up 5.36%
As of Wednesday, January 21, CalciMedica, Inc.’s CALC share price has surged by 5.36%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why CalciMedica, Inc.’s (CALC) Stock Is Up 5.17%
As of Tuesday, January 20, CalciMedica, Inc.’s CALC share price has surged by 5.17%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why CalciMedica, Inc.’s (CALC) Stock Is Up 5.89%
As of Friday, January 16, CalciMedica, Inc.’s CALC share price has surged by 5.89%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | CALC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $14.8 | $674.5 | 8% |
|
| Shares Out (Mil) | 3.4 | 43.5 | 11% |
|
| Institutional Ownership | 77.5% | 84.6% | 47% |
|
| Float (Mil) | 3.8 | 47.3 | 9% |
|
| Beta | 1.01 | 0.71 | 61% |
|
| Avg Daily Volume (000s) | 118 | 290 | 39% |
|
| Price Change (52-week) |
(86.3%) | 69.3% | 5% |
|
| Growth | CALC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (14.3%) | (1.4%) | 26% |
|
| EPS (5yr) | 19.3% | 15.0% | 67 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (31.5%) | (15.0%) | 18% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CALC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($21) | ($11) | 23% |
|
| EPS (TTM) | ($6.653) | ($0.700) | 6% |
|
| Operating Cash Flow (TTM) (Mil) | ($19) | ($6) | 15% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $9 | $6 | 28% |
|
| Enterprise Value (Q1) (Mil) | $5 | $536 | 5% |
|
| Valuation | CALC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.41 | 2.80 | 57% |
|
| P/E | na | 17.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CALC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.1% | na |
|
| Net Margin | na | (1.4%) | na |
|
| ROA | (110.1%) | (24.1%) | 5% |
|
| ROE | (365.7%) | (21.0%) | 2% |
|
| Liabilities to Assets | 71.7% | 32.3% | 67% |
|
| F-Score | 2 | 3 | 7% |
|
CalciMedica, Inc. did not pass any screens on 9/4/2026.
